Following its economic rise in recent decades, driven by innovation across a wide variety of powerhouse industries, South Korea is setting its sights on the next generation of technological growth-including new strategies to globalize and industrialize the nation’s pharmaceutical and healthcare sector.
How drug developers can include strategy in R&D portfolio review to decide how to allocate resources across current and future projects.
As manufacturers look to commercialize new medicines, it is important to evaluate partners that can provide a fully integrated offering aligned to product performance goals and offer a seamless customer experience.
Each year, the success of cell and gene therapy becomes clearer, but what do we really know about it?
The lifeblood of our coverage are the many interviews we conduct with industry executives-and the unique stories and insights they provide. Here, I highlight excerpts from a selection of wide-ranging conversations from the past year.
Life sciences therapies are moving away from a one-size-fits-all approach to a targeted approach using a patient's own genetic information and immune system to treat previously incurable diseases.
Outside of raising prices, pharma can generate new revenue from just three other sources, write Tom Kottler.
Click the title above to open the Pharmaceutical Executive April 2019 issue in an interactive PDF format.
Declaring it a “strategic sector for priority development,” China has opened up the floodgates for sweeping reforms of the nation’s healthcare infrastructure-a watershed moment for the Chinese pharmaceutical and healthcare industries, where all stakeholders will have to adapt to the new rules of the game.
Regulatory Affairs Professionals Society's Executive Director, Paul Brooks, discusses the looming uncertainty about what will happen after the UK leaves the European Union as many important details remain unclear.
KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
Patient preferences are increasingly seen as valuable in healthcare policy decision-making, but such studies are not always easy to design and implement, writes Nick Hicks.
The discrepancies between trial and real-life patient conditions are such that Real-World Evidence (RWE) can be utilized to supplement this process.
The FDA planned budget features added funds allotted to improved oversight of drugs, biologics, and medical devices.
![Controlled Correspondence article graphic[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/53857f180a628d842a88ca8e05e255aa63d03c1a-1672x801.jpg?w=350&fit=crop&auto=format)
As part of FDA’s ongoing effort to modernize interactions with industry, FDA launched a portal to help with submissions of controlled correspondence via email instead of manual data entry.
Michael J. Hennessy Jr., president of MJH Associates‚ Inc., answers questions about the acquisition of UBM Life Sciences media brands and his company’s perspective on the evolving biopharma landscape.
We’re about to lose the most tech-savvy FDA chief in recent memory, writes Pratap Khedkar.
Brenda Snow talks to Pharm Exec about the creation of Snow Companies, the first full-service agency to bring strategic, regulatory-compliant, real-life patient stories to direct-to-patient initiatives.
Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.